Crohn’s Disease: A Case for MAP Targeted Therapy

January 22, 2016 Papers 0

In this new paper, Crohn’s Disease: A Case for MAP Targeted Therapy, Leonie Marloes Vogt makes a compelling case for further investigation into the role of MAP as the cause of Crohn’s disease and highlights how this could lead to new treatment options. We fully agree with you Leonie!

Crohn’s disease (CD) is a severe intestinal inflammatory disease, for which currently no full cure is possible, and of which the pathogenesis is still not fully elucidated. Intestinal bacteria are thought to play a role in the onset, combined with environmental factors, immune factors, and genetic susceptibility of the host. However, we do not fully understand the nature of the disease yet, and as a consequence, this lack in our knowledge may prevent us from developing effective and curative therapies. If we are able to revisit our views on involvement of Mycobacterium avium ssp. paratuberculosis (MAP) a as an important player in this disease, this might open up new options for therapeutic targets.